CDK4/6
49 programs · 48 companies
Programs
49
Companies
48
Active Trials
34
Targeting CDK4/6
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Motavorutinib | Amgen | Phase 3 | LN | |
| Ribozanubrutinib | Regeneron | Phase 1 | SMAADHD | |
| MRN-5715 | Moderna | NDA/BLA | FabryRA | |
| Elralucimab | Axsome | Phase 2 | Heart FailureEpilepsy | |
| Rimanaritide | Agios | Phase 1 | Wilms | |
| Lisosotorasib | Sobi | Phase 2/3 | MCCPV | |
| Adagrafutibatinib | Astellas | Phase 2 | UCDMD | |
| 644-5754 | PharmaEssentia | Phase 3 | CeliacCSU | |
| Nidacagene | Boehringer Ingelheim | Phase 2 | Urothelial Ca | |
| Mavulucimab | Sumitomo Pharma | NDA/BLA | CSU | |
| JOH-IIT-455 | Johns Hopkins | Approved | Huntington's | |
| RIN-7561 | Ring Ther | Approved | DMD | |
| Nidanesiran | GenEdit | Approved | RA | |
| CRV-1020 | CervoMed | Approved | PSPADPKD | |
| Zoritenlimab | Flare Ther | Preclinical | ADPKDHNSCC | |
| Polasacituzumab | Nuo Therapeutics | Phase 1/2 | IPF | |
| SWT-3857 | SpringWorks | Phase 1 | FLGIST | |
| Ribocilimab | Rigel Pharma | Phase 3 | Wilms | |
| TRV-9337 | Trevena | Approved | AML | |
| Pemifotisoran | Ascentage | Phase 1/2 | CeliacMeso | |
| 068-872 | Celltrion | Approved | SCLC | |
| GC-6461 | GC Cell | Preclinical | CML | |
| Polalucimab | OliX Pharma | Phase 2 | AngelmanFabry | |
| DYN-1761 | Dyno Ther | Phase 1 | LN | |
| GH-9188 | Guardant Health | Phase 1 | NBAML | |
| Motasacituzumab | Orchard (Kyowa) | Approved | MG | |
| TNG-3308 | Transgene | Preclinical | ACCCeliac | |
| DAI-7966 | Daiichi Sankyo EU | Preclinical | MG | |
| 488-6595 | CellSource | Approved | GISTGBM | |
| 532-4982 | Zydus Life | Phase 3 | SchizophreniaNB | |
| SVA-6795 | Sinovac | NDA/BLA | CRCNB | |
| Datorasimod | Indivior | Phase 2/3 | ThymomaCRC | |
| Rimanaritide | Hikma Pharma | Phase 2/3 | NASHHS | |
| Teratenlimab | BTG (Boston Sci) | Phase 2 | Urothelial Ca | |
| ACE-3611 | Acerus (Sun) | NDA/BLA | EoEPancreatic Ca | |
| Fixatenlimab | Nanobiotix | Phase 1/2 | Crohn's | |
| ACH-2340 | Ache Laboratorios | Phase 3 | MesoPNH | |
| APN-7734 | Aspen Pharmacare | Phase 1 | DLBCLRett | |
| KAR-IIT-192 | Karolinska Inst | Phase 3 | Fabry | |
| TAT-IIT-198 | Tata Memorial Hosp | Phase 1 | PTSD | |
| ASA-IIT-156 | Asan Medical Center | Phase 1/2 | Crohn's | |
| ASA-IIT-476 | Asan Medical Center | Phase 3 | CLL | |
| CAM-IIT-432 | CAMS Peking Union | Preclinical | ALL | |
| NAT-IIT-589 | Natl Taiwan Univ Hosp | Phase 1/2 | OCD | |
| BEA-1452 | Beacon Pharma | Phase 1 | RettWM | |
| Semacapivasertib | Zhejiang Medicine | Preclinical | RBAML | |
| Ivonaritide | Cardiol Therapeutics | Phase 2 | Heart FailureOvarian Ca | |
| VEE-7651 | Veeva Systems | Preclinical | MDDObesity | |
| Teraosocimab | GenNBio | Phase 3 | MigraineSLE |